CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations
1. CRMD reported Q3 earnings of $1.26, beating estimates significantly. 2. Sales surged to $104.27 million, up from $11.5 million last year. 3. Full-year 2025 revenue guidance raised to $390-$410 million from $283.69 million. 4. DefenCath utilization drove $88.8 million in revenue this quarter. 5. CRMD stock increased 12.06% following the earnings report.